Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-07

FDA Approved: MONTELUKAST — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for Montelukast submitted by BluePoint Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Montelukast (Montelukast)

Snippet

SUPPL AP for MONTELUKAST (MONTELUKAST)